The company is preparing a Phase 3 trial of enobosarm with a novel formulation that could extend its patent life.

Commissioner Martin Makary and two of his deputies aim to meet with drugmaker CEOs to discuss how the agency can “modernize” ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

The agency recommends manufacturers update their vaccines to target the JN.1 strain. At the same time, HHS head Robert F.

The FDA has placed a clinical hold on the study while Rocket works with trial monitors and experts to investigate the cause ...

The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach ...

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

The advisory committee, which met after the agency rolled out new vaccine guidelines, said companies should tailor their ...

Tumors with low- and ultra-low levels of a protein called HER2 are treatable with Enhertu, but harder to identify. New ...

Still, the therapies’ modest benefit as a maintenance therapy points to how better treatments are needed for small cell lung ...

Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...